View all news

Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma

01/30/2024

Multimedia Files:

View all news
Questions? Please contact us:
1-800-950-5089 investor-relations@its.jnj.com